The frontline standard-of-care regimen for patients with higher-risk MDS and some with lower-risk MDS remain hypomethylating agents, such as azacitidine, decitabine, and decitabine/cedazuridine.
Kelly Chien, MD
Kelly Chien, MD, is an assistant Professor in the department of leukemia, division of cancer medicine, The University of Texas MD Anderson Cancer Center, in Houston, TX.
Articles by Kelly Chien, MD
Latest Updated Articles
Addressing MDS Treatment Gap Post Hypomethylating FailurePublished: March 21st 2024 | Updated: